DPP4 and diabetic ketoacidosis: In an RCT and a nationwide cohort study, the results showed no increased risk of hypoglycaemia with SGLT-2i monotherapy [42, 43]; however, SGLT-2i were associated with approximately twice the risk of diabetic ketoacidosis as DPP4 inhibitors [44].